Composite end points and competing risks analysis

被引:1
|
作者
Dayan, Victor [1 ]
Grant, Stuart W. [2 ]
Brophy, James M. [3 ]
Barili, Fabio [4 ]
Freemantle, Nick [5 ]
机构
[1] Univ Republica, Ctr Cardiovasc Univ, Hosp Clin, Cardiac Surg Dept, Montevideo, Uruguay
[2] Univ Manchester, Manchester Univ Hosp Fdn Trust, Div Cardiovasc Sci, ERC, Manchester, England
[3] McGill Univ, Hlth Ctr, Cardiol Dept, Montreal, PQ, Canada
[4] Santa Croce Hosp, Dept Cardiac Surg, Cuneo, Italy
[5] UCL, Inst Clin Trials, London, England
关键词
Composite outcomes; Competing risks; Statistics; WIN RATIO; CARDIOVASCULAR TRIALS; CLINICAL-TRIALS; SURVIVAL-DATA;
D O I
10.1093/icvts/ivae126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Composite end points are common primary outcomes in clinical trials. Their main benefit of utilizing a composite outcome is increasing the number of primary outcome events, meaning fewer participants are required to deliver an adequately powered trial. By combining multiple important end points in the primary outcome rather than having to select only 1, composite end points potentially make clinically meaningful benefits easier to detect and avoid ranking outcomes hierarchically. However, there are a number of important considerations when designing and interpreting clinical trials that utilize composite end points. In this Statistical Primer, issues with composite end points such as competing events, halo effect, risk of bias, time-to-event limitations and the win ratio are discussed in the context of real world clinical trials. A composite end point includes 2 or more different individual end points that are combined so that the occurrence of any of the individual end points results in the occurrence of the composite end point.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Pitfalls of Using Composite Primary End Points in the Presence of Competing Risks
    Mell, Loren K.
    Jeong, Jong-Hyeon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4297 - 4299
  • [2] Criteria for use of composite end points for competing risks-a systematic survey of the literature with recommendations
    Manja, Veena
    AlBashir, Siwar
    Guyatt, Gordon
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2017, 82 : 4 - 11
  • [3] Methods to evaluate risks for composite end points and their individual components
    Glynn, RJ
    Rosner, B
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (02) : 113 - 122
  • [4] Competing risks analysis of lamb mortality in a terminal sire composite population
    Southey, BB
    Rodríguez-Zas, SL
    Leymaster, KA
    [J]. JOURNAL OF ANIMAL SCIENCE, 2004, 82 (10) : 2892 - 2899
  • [5] Cumulative incidence in competing risks data and competing risks regression analysis
    Kim, Haesook T.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (02) : 559 - 565
  • [6] COMPETING RISKS IN MORTALITY ANALYSIS
    CHIANG, CL
    [J]. ANNUAL REVIEW OF PUBLIC HEALTH, 1991, 12 : 281 - 307
  • [7] An Introduction to Competing Risks Analysis
    Pintilie, Melania
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2011, 64 (07): : 599 - 605
  • [8] Semiparametric competing risks analysis
    Canals-Cerda, Jose
    Gurmu, Shiferaw
    [J]. ECONOMETRICS JOURNAL, 2007, 10 (02): : 193 - 215
  • [9] Competing approaches to analysis of failure times with competing risks
    Farley, TMM
    Ali, MM
    Slaymaker, E
    [J]. STATISTICS IN MEDICINE, 2001, 20 (23) : 3601 - 3610
  • [10] A Competing Risks Analysis of Corporate Survival
    He, Qing
    Chong, Terence Tai-Leung
    Li, Li
    Zhang, Jun
    [J]. FINANCIAL MANAGEMENT, 2010, 39 (04) : 1697 - 1718